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MAC and 12 had no conditioning. 31 patients engrafted after
the 2nd HSCT. The overall survival for patients who under-
went a 2nd HSCT was 61% (27/44) with a median overall
survival of 3.8 years (range: 0.2yrs to >10 yrs) and better
survival for patients with non-malignant (21/30) versus
malignant disease (6/14). There was no difference in survival
between patients with primary versus secondary graft fail-
ures. Infection was the primary cause of death (9/17). For 13
patients who failed to engraft after 2nd HSCT, 3 patients died
and 10 patients received a 3rd HSCT of whom 5 patients
survive. Thus 61% of pediatric patients can achieve graft
salvage from a second transplant, and half of the continuing
graft failures can be rescued by a third HSCT.284
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Several studies have demonstrated that a therapeutic
Cyclosporine (CsA) concentration within one week following
graft infusion correlates with a reduced risk of grade III-IV
acute graft versus host disease (aGVHD). Therefore, to begin
a quality improvement (QI) project we performed a retro-
spective chart analysis to determine when, using our stan-
dard approach to initial CsA dosing, our allogeneic bone
marrow transplant patients ﬁrst achieved therapeutic CsA
levels (Trough¼150-250ng/ml). Fifty three allogeneic trans-
plants were performed during the period assessed, of which
47 were eligible for evaluation. Patients were excluded from
analysis due to alternate GVH prophylaxis or major drug
interactions. In this historical cohort, CsA prophylaxis was
initiated as follows: loading with Cyclosporine, 2mg/kg/dose
IV Q 12 hrs for two days (day -2 and day-1) then decreasing
to 1.5mg/kg/dose IV Q 12 hrs. Using this approach, 34% of
patients had therapeutic levels within the ﬁrst 3 days
following transplant. Following this baseline analysis, we
initiated a QI intervention aimed at achieving a therapeutic
trough CsA level in at least 80% of patients by Day +3. To
accomplish this, the following new CsA regimen was insti-
tuted. Patients 5 years or older received Cyclosporine at
2.5mg/kg/dose IV Q 12 hrs beginning on day -3, and patients
less than 5 years of age received Cyclosporine at 2.5mg/kg/
dose IV Q 8 beginning on day -3. If the trough level was
subtherapeutic (below 100 NG/ML) on day 0, we gave an
extra 2mg/kg/loading dose IV, then increased the basal dose
by20%. If the level was between 100 and 149, we increased
the basal dose by 20% without an additional loading dose.
The impact of this intervention on the percentage of patientsachieving therapeutic CsA levels between Day 0 and Day + 3
was then assessed. To date, we have performed 28 trans-
plants under the new CsA regimen. Of these, 23 patients
were evaluable. Five patients were excluded per the previous
criteria. Using the new dosing guidelines, 87% of patients
achieved therapeutic CsA levels in the Day 0 to Day +3
window. This represent a statiscally signiﬁcant improvement
over our previous dosing regimen in which 34% of patients
achieved therapeutic CsA levels by Day +3 (P < .0003). No
patients had supratherapeutic CsA levels, deﬁned as greater
than 400 ng/ml within the ﬁrst 3 days post transplant. One
patient did exhibit nephrotoxicity, deﬁned as a persistent
doubling of the serum creatinine by Day +10. This patient
also had Adeno and BK viruria at Day 0 which confounds
assessment of causation. Overall, the revised dosing regimen
is both well tolerated and more effective in achieving the
targeted CsA level in 80% of cases (95% conﬁdence interval,
68-95%). Following completion of this project, we plan
further analyses to determine whether this practice change
has impacted rates of aGVHD in our patient population.285
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In adults, hepatic complications following allogeneic
hematopoietic stem cell transplantation (AlloHSCT) are
associated with signiﬁcant morbidity and transplant related
mortality (TRM). However, there is a paucity of parallel data
on the incidence of, and risk factors for, liver injury (LI) and
the impact of LI on TRM in pediatric AlloHSCT recipients.
Methods: We compared total bilirubin, direct bilirubin and
alanine aminotransferase values pre-AlloHSCT and at
1month, day +100 and 12 months post-AlloHSCT in 248
patients following myeloablative conditioning (MAC) or
reduced toxicity/reduced intensity conditioning (RTC/RIC).
Liver injury was deﬁned as  Grade 2 toxicities according to
the NCI CTCAE 3.0/4.0 or total bilirubin 1.95mg/dL (1.5 times
above upper limit of normal). Univariate and multivariate
logistic regression models were used to identify risk factors
for the incidences of LI and TRM.
Results: 248 eligible patients received MAC (n¼109) or RTC/
RIC AlloHSCT (n¼139). The incidence of LI at 1 month post-
AlloSCT was signiﬁcantly higher in MAC vs. RTC/RIC
AlloHSCT based on total bilirubin levels (21.9% vs. 7.8%; P ¼
.0067). There was no signiﬁcant difference in LI pre-
AlloHSCT, LI at day +100 and 12 months post-AlloHSCT
between the two groups. The TRM among patients with LI at
1 month post-AlloHSCT was as 64.2% (CI95 49%, 79.4%)
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did not have LI at 1 month post- AlloHSCT. On multivariate
analysis, only bloodstream bacterial infections (P ¼ .0059)
and invasive fungal infections (P ¼ .0020) were signiﬁcant
risk factors for developing LI at 1 month. On multivariate
analysis for risk factors for TRM, only LI at 1 month post-
AlloHSCT (P ¼ .0001), primary graft failure (P ¼ .0096) and
bloodstream bacterial infections (P ¼ .0328) were signiﬁcant.
However, LI prior to AlloHSCT conditioning was not associ-
ated with higher TRM.
Conclusions: TRM among pediatric patients with LI at 1
month post-AlloHSCT is extremely high, with infections
being the primary risk factor for LI.Table 1
Relapse rates, by MRD286
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Extracorporeal photopheresis (ECP) is an established
second line treatment option for graft versus host disease
post hematopoietic progenitor cell transplant. At our center
the Therakos Cellex has replaced the UVAR-XTS machine for
ECP since 2009. We reviewed the records of 385 procedures
using the Therakos Cellex. Nine patients underwent ECP for
GVHD. The median age was 13.5 years (range 3.7 to 24) and
weight was 49.2 kg (range 18.5-86.3). ECP was initiated at
a median of 7.5 months (range 0.3-34.8) from the onset of
GVHD. The mean duration per procedure was 106 minutes
(range 60-205). Fifteen (3.9%) procedures were cancelled and
10 (2.6%) were delayed with central venous line (CVL) issues
being the most frequent problem. Instillation of prophylactic
tissue plasminogen activator (tPA) in the CVL lumens prior to
a procedure was instituted 6 months before the end of study
period, to reduce the incidence of CVL related occlusions and
sluggish returns. With change in practice, fewer CVL related
occlusions were observed (4.7% vs. 2.3%). There was one
episode of CVL-associated thrombosis and one episode of
delayed bleeding (mild and spontaneously resolved). There
were four episodes of viral reactivation, 4 CVL-associated
infections (1142 catheter days) and 1 episode of systemic
inﬂammatory response syndrome. No patient experienced
hypotension that requiredmedical intervention. Although no
additional adverse events were noted, there was consider-
able blood exposure in the smallest patients because of the
need for machine blood prime. The Therakos Cellex appears
to be safe and well-tolerated in 385 procedures performed in
our institution. This is the ﬁrst report regarding the safety
and tolerability of this device for ECP in children and young
adults.Disease MRD 0.01% Total (n) Relapse (n) Relapse
Rates
Acute
lymphoblastic
leukemia
No 20 7 35%
Yes 11 7 64%
Acute myelogenous
leukemia
No 15 3 20%
Yes 11 4 36%
Mixed phenotype
acute leukemia
No 8 3 38%
Yes 1 0 0%287
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Background: Relapse is the primary cause of treatment
failure post alloHCT. We sought to identify risk factors that
predict relapse of hematologic malignancies after allogeneic
hematopoietic cell transplantation (alloHCT) to identify
those at highest risk of relapse who may beneﬁt from novel
therapies.
Design: This was a single institution, retrospective cohort
study of children with acute lymphoblastic leukemia (ALL),
acute myelogenous leukemia (AML), mixed phenotypic acute
leukemia (MPAL) and myelodysplastic syndrome (MDS) who
had undergone alloHCT between 1/1/2003 and 12/31/2010.
Relapse was deﬁned as any evidence of increasing disease
post-alloHCT, including minimal residual disease (MRD).
Relapse-free survival (RFS) was estimated by the Kaplan-
Meier method and the log-rank test used to assess univariate
associations with various characteristics. A Cox proportional
hazards model was used to identify factors jointly associated
with RFS.
Results: Of 70 children who underwent a myeloablative HCT
for MDS or acute leukemia in complete remission at the time
of HCT, 24 (34%) relapsed at a median of 214 days (range 1
month- 57 months) post-HCT. Relapse rates by disease were
14/31 (45%) for ALL; 7/26 (27%) for AML; 3/9 (33%) for MPAL;
0/4 (0%) for MDS. Univariate analysis demonstrated that
black race, central nervous system (CNS) disease at diagnosis
(Figure 1), greater number of regimens given to induce
remission and MRD pre-HCT were associated with higher
relapse probability. In a Cox model, either two or more
regimens needed to achieve remission or the presence of
both pre-HCT MRD and CNS disease were approximately
equally predictive of increased relapse risk. In patients with
ALL, CNS disease was more highly associated with relapse
risk than MRD. For those who were MRD negative, based
on 19 total patients, the presence of CNS disease at
diagnosis (n¼2) was signiﬁcantly associated with higher
relapse risk (P < .0001).
Conclusion: We identiﬁed CNS involvement at diagnosis as
a novel risk factor associated with relapse risk after alloHCT.
This may be due to inherent biologic differences leading to
higher risk disease, or as a sanctuary site, the CNSmay be less
amenable to an allogeneic effect. These patients may beneﬁt
from earlier or more intensive CNS-directed therapy to
reduce relapse risk. Validation of these risk factors in a larger
population and development of a prognostic score to identify
those at highest risk of relapse in addition to a biology study
to evaluate for MRD in the CNS using ﬂow cytometery is
planned. The goal is for prospective use of this prognostic
tool in the development of relapse prevention trials.
